Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey #MMPMID33237663
Erdem HA; Korkma PE; Caglayan D; Isikgoz Tasbakan M; Yamazhan T; Tasbakan MS; Sayiner A; Gokengin D
Turk J Med Sci 2021[Jun]; 51 (3): 912-920 PMID33237663show ga
BACKGROUND/AIM: The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia. MATERIALS AND METHODS: This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. RESULTS: Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written. CONCLUSION: This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.
|*COVID-19 Drug Treatment[MESH]
|*Pandemics[MESH]
|*SARS-CoV-2[MESH]
|Adult[MESH]
|Aged[MESH]
|Amides/*therapeutic use[MESH]
|Antiviral Agents/therapeutic use[MESH]
|COVID-19/epidemiology[MESH]
|Female[MESH]
|Follow-Up Studies[MESH]
|Humans[MESH]
|Intensive Care Units/*statistics & numerical data[MESH]
free
free
free
Turk+J+Med+Sci 2021 ; 51 (3): 912-920
